- Home
- YMAB vs ALMS Comparison
YMAB vs ALMS Comparison
Compare YMAB & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- ALMS
- Stock Information
- Founded
- YMAB 2015
- ALMS 2021
- Country
- YMAB United States
- ALMS United States
- Employees
- YMAB N/A
- ALMS N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- ALMS
- Sector
- YMAB Health Care
- ALMS
- Exchange
- YMAB Nasdaq
- ALMS NYSE
- Market Cap
- YMAB 482.4M
- ALMS 469.0M
- IPO Year
- YMAB 2018
- ALMS 2024
- Fundamental
- Price
- YMAB $6.19
- ALMS $7.41
- Analyst Decision
- YMAB Strong Buy
- ALMS Strong Buy
- Analyst Count
- YMAB 10
- ALMS 6
- Target Price
- YMAB $21.10
- ALMS $29.60
- AVG Volume (30 Days)
- YMAB 417.3K
- ALMS 121.0K
- Earning Date
- YMAB 02-27-2025
- ALMS 02-15-2025
- Dividend Yield
- YMAB N/A
- ALMS N/A
- EPS Growth
- YMAB N/A
- ALMS N/A
- EPS
- YMAB N/A
- ALMS N/A
- Revenue
- YMAB $84,553,000.00
- ALMS N/A
- Revenue This Year
- YMAB $6.09
- ALMS N/A
- Revenue Next Year
- YMAB $19.62
- ALMS N/A
- P/E Ratio
- YMAB N/A
- ALMS N/A
- Revenue Growth
- YMAB N/A
- ALMS N/A
- 52 Week Low
- YMAB $6.01
- ALMS $6.75
- 52 Week High
- YMAB $20.90
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- YMAB 19.68
- ALMS N/A
- Support Level
- YMAB $6.05
- ALMS N/A
- Resistance Level
- YMAB $6.81
- ALMS N/A
- Average True Range (ATR)
- YMAB 0.49
- ALMS 0.00
- MACD
- YMAB -0.02
- ALMS 0.00
- Stochastic Oscillator
- YMAB 6.90
- ALMS 0.00
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.